These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 32344513

  • 1. Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.
    Feldmann DP, Heyza J, Zimmermann CM, Patrick SM, Merkel OM.
    Molecules; 2020 Apr 24; 25(8):. PubMed ID: 32344513
    [Abstract] [Full Text] [Related]

  • 2. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM.
    Nutrients; 2018 Nov 03; 10(11):. PubMed ID: 30400270
    [Abstract] [Full Text] [Related]

  • 3. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM.
    DNA Repair (Amst); 2010 Jul 01; 9(7):745-53. PubMed ID: 20418188
    [Abstract] [Full Text] [Related]

  • 4. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
    Li C, Li T, Huang L, Yang M, Zhu G.
    Chem Asian J; 2019 May 02; 14(9):1570-1576. PubMed ID: 30843348
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM, Astell KR, Ritchie AM, Shave S, Houston DR, Bakrania P, Jones HM, Khurana P, Wallace C, Chapman T, Wear MA, Walkinshaw MD, Saxty B, Melton DW.
    DNA Repair (Amst); 2015 Jul 02; 31():19-28. PubMed ID: 25956741
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
    Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY, You HJ.
    Biochem Biophys Res Commun; 2005 Feb 04; 327(1):225-33. PubMed ID: 15629453
    [Abstract] [Full Text] [Related]

  • 11. The knock-down of ERCC1 but not of XPF causes multinucleation.
    Rageul J, Frëmin C, Ezan F, Baffet G, Langouët S.
    DNA Repair (Amst); 2011 Sep 05; 10(9):978-90. PubMed ID: 21839691
    [Abstract] [Full Text] [Related]

  • 12. Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
    Ganzinelli M, Linardou H, Alvisi MF, Caiola E, Lo Russo G, Cecere FL, Bettini AC, Psyrri A, Milella M, Rulli E, Fabbri A, De Maglie M, Romanelli P, Murray S, Broggini M, Marabese M, Garassino MC.
    ESMO Open; 2021 Feb 05; 6(1):100034. PubMed ID: 33422766
    [Abstract] [Full Text] [Related]

  • 13. Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment.
    He L, Wang X, Liu K, Wu X, Yang X, Song G, Zhang B, Zhong L.
    Gene; 2019 Apr 05; 691():70-76. PubMed ID: 30584903
    [Abstract] [Full Text] [Related]

  • 14. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY, Qu QX, Mi RR, Qi J.
    Zhonghua Zhong Liu Za Zhi; 2008 Mar 05; 30(3):184-7. PubMed ID: 18756932
    [Abstract] [Full Text] [Related]

  • 15. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Mesquita KA, Alabdullah M, Griffin M, Toss MS, Fatah TMAA, Alblihy A, Moseley P, Chan SYT, Rakha EA, Madhusudan S.
    Gynecol Oncol; 2019 May 05; 153(2):416-424. PubMed ID: 30797591
    [Abstract] [Full Text] [Related]

  • 16. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing gene 1 in lung cancer cell A549/DDP].
    Gao Y, Su D, Ying L, Lv W, Ma S.
    Zhongguo Fei Ai Za Zhi; 2010 Sep 05; 13(9):846-9. PubMed ID: 20840811
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
    Lan L, Hayashi T, Rabeya RM, Nakajima S, Kanno Si, Takao M, Matsunaga T, Yoshino M, Ichikawa M, Riele Ht, Tsuchiya S, Tanaka K, Yasui A.
    DNA Repair (Amst); 2004 Feb 03; 3(2):135-43. PubMed ID: 14706347
    [Abstract] [Full Text] [Related]

  • 19. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
    Liu GY, Qu QX, Mi RR, Qi J.
    Zhonghua Fu Chan Ke Za Zhi; 2006 May 03; 41(5):339-42. PubMed ID: 16762192
    [Abstract] [Full Text] [Related]

  • 20. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
    Kirschner K, Melton DW.
    Anticancer Res; 2010 Sep 03; 30(9):3223-32. PubMed ID: 20944091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.